22q11.2 Deletion Syndrome (22q11DS) represents one of the greatest known genetic risk factors for the development of psychotic illness. Neuroimaging studies of 22q11DS offer a unique opportunity to investigate developmental trajectories of risk.The ENIGMA-22q working group aims to carry out meta-analysis of existing structural MRI and DTI data of children and adults with the 22q11.2 deletion and healthy controls. The analysis is expected to include data of over 500 cases and a comparable number of healthy individuals available from the studies of multiple groups with large cohorts of 22q11DS patients, across the US and internationally. Special points of attention will be given to differential patterns of brain development in 22q11DS patients with psychotic and/or autism spectrum symptoms. In addition, we expect to analyze developmental aspects of altered brain morphology. We also plan to compare 22q meta-analytic results to those of idiopathic schizophrenia (ENIGMA-SZ).
If you are interested in joining ENIGMA-22q, please contact Carrie Bearden.
List of ENIGMA-22q members (as of November 2016)ENIGMA on social media: